The peripheral nervous system serves as the communication network between the brain, spinal cord, muscles, and sensory organs. In dogs affected by Adult-Onset Neuropathy, degeneration of peripheral nerves disrupts the transmission of signals throughout the body. This progressive nerve damage can impair muscle function and coordination, leading to increasing physical limitations over time.
Clinical signs of AON generally appear in mature or older dogs, although the age of onset and severity may vary depending on the individual and the specific genetic mutation involved. Early symptoms may include mild weakness in the hind limbs, difficulty jumping, reduced stamina, or an abnormal gait. As the disease progresses, affected dogs may develop muscle wasting, stumbling, loss of balance, weakness in multiple limbs, difficulty climbing stairs, and reduced ability to exercise. Some dogs may also experience changes in voice, swallowing difficulties, or reduced reflexes due to nerve involvement. In advanced stages, mobility can become significantly impaired.
The AON DNA Health Test is designed to identify the genetic mutation associated with Adult-Onset Neuropathy. Testing is simple and non-invasive, typically requiring a cheek swab or blood sample. The collected sample is analyzed in a specialized laboratory to determine the dog's genetic status. Since DNA remains unchanged throughout life, testing can be performed at any age, including long before clinical signs develop.
Results are generally reported in one of three categories:
- Clear (Normal): The dog does not carry the AON mutation and cannot pass it to offspring.
- Carrier: The dog carries one copy of the mutation but is typically unaffected by the disease. However, it can pass the mutation to future generations.
- Affected/At Risk: The dog carries two copies of the mutation and has a significantly increased likelihood of developing Adult-Onset Neuropathy during its lifetime.
Genetic testing for AON provides valuable information for breeders, veterinarians, and dog owners. Breeders can use test results to make informed mating decisions that help reduce the prevalence of the disorder while maintaining healthy genetic diversity within the breed population. Avoiding the breeding of two carrier dogs can significantly decrease the risk of producing affected puppies.
For dog owners, understanding a dog's genetic status allows for proactive health monitoring and early veterinary intervention. Dogs identified as at risk may benefit from regular neurological examinations, mobility assessments, and supportive care aimed at maintaining comfort and quality of life. While there is currently no cure for Adult-Onset Neuropathy, early recognition and ongoing management can help address symptoms and support affected dogs as the disease progresses.
The Adult-Onset Neuropathy (AON) Health Test is a reliable genetic screening tool that supports responsible breeding practices, promotes canine neurological health, and helps reduce the impact of this inherited disorder in future generations. Through early detection and informed breeding decisions, breeders and owners can contribute to healthier dogs and improved long-term welfare.
